These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19321503)

  • 21. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
    Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Hassink EA; van Eck-Smit BL; Borleffs JC; Lange JM; Reiss P
    HIV Clin Trials; 2007; 8(5):337-44. PubMed ID: 17956835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.
    Miró O; Garrabou G; López S; Deig E; Vidal I; Infante AB; Cardellach F; Casademont J; Pedrol E
    Antivir Ther; 2006; 11(5):625-30. PubMed ID: 16964831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
    Rosso R; Nasi M; Di Biagio A; Repetto E; Dentone C; Pinti M; Nemes E; Ferraresi R; Mussini C; Esposito R; Viscoli C; Cossarizza A
    Pediatr Infect Dis J; 2008 Jan; 27(1):17-21. PubMed ID: 18162932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial.
    Menezes CN; Duarte R; Dickens C; Dix-Peek T; Van Amsterdam D; John MA; Ive P; Maskew M; Macphail P; Fox MP; Raal F; Sanne I; Crowther NJ
    HIV Med; 2013 Apr; 14(4):217-25. PubMed ID: 23036096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).
    Tebas P; Zhang J; Yarasheski K; Evans S; Fischl MA; Shevitz A; Feinberg J; Collier AC; Shikuma C; Brizz B; Sattler F;
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):193-200. PubMed ID: 17527093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.
    Carr A; Ritzhaupt A; Zhang W; Zajdenverg R; Workman C; Gatell JM; Cahn P; Chaves R
    AIDS; 2008 Nov; 22(17):2313-21. PubMed ID: 18981770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
    Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
    N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.
    Haubrich RH; Riddler SA; DiRienzo AG; Komarow L; Powderly WG; Klingman K; Garren KW; Butcher DL; Rooney JF; Haas DW; Mellors JW; Havlir DV;
    AIDS; 2009 Jun; 23(9):1109-18. PubMed ID: 19417580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients.
    Cassetti I; Madruga JV; Suleiman JM; Etzel A; Zhong L; Cheng AK; Enejosa J;
    HIV Clin Trials; 2007; 8(3):164-72. PubMed ID: 17621463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.
    John M; McKinnon EJ; James IR; Nolan DA; Herrmann SE; Moore CB; White AJ; Mallal SA
    J Acquir Immune Defic Syndr; 2003 May; 33(1):29-33. PubMed ID: 12792352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
    Carr A; Workman C; Smith DE; Hoy J; Hudson J; Doong N; Martin A; Amin J; Freund J; Law M; Cooper DA;
    JAMA; 2002 Jul; 288(2):207-15. PubMed ID: 12095385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.
    McComsey GA; Lo Re V; O'Riordan M; Walker UA; Lebrecht D; Baron E; Mounzer K; Frank I
    Clin Infect Dis; 2008 Apr; 46(8):1290-6. PubMed ID: 18444869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
    Anastos K; Lu D; Shi Q; Tien PC; Kaplan RC; Hessol NA; Cole S; Vigen C; Cohen M; Young M; Justman J
    J Acquir Immune Defic Syndr; 2007 May; 45(1):34-42. PubMed ID: 17460470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
    Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S
    Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study.
    Domingo P; Gutierrez Mdel M; Gallego-Escuredo JM; Torres F; Mateo GM; Villarroya J; de los Santos I; Domingo JC; Villarroya F; Del Rio L; Estrada V; Giralt M
    PLoS One; 2014; 9(2):e89088. PubMed ID: 24586518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
    Podzamczer D; Ferrer E; Sanchez P; Gatell JM; Crespo M; Fisac C; Lonca M; Sanz J; Niubo J; Veloso S; Llibre JM; Barrufet P; Ribas MA; Merino E; Ribera E; Martínez-Lacasa J; Alonso C; Aranda M; Pulido F; Berenguer J; Delegido A; Pedreira JD; Lérida A; Rubio R; del Río L;
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):139-47. PubMed ID: 17106274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
    Wandeler G; Gerber F; Rohr J; Chi BH; Orrell C; Chimbetete C; Prozesky H; Boulle A; Hoffmann CJ; Gsponer T; Fox MP; Zwahlen M; Egger M;
    Antivir Ther; 2014; 19(5):521-5. PubMed ID: 24296645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
    Benn P; Sauret-Jackson V; Cartledge J; Ruff C; Sabin CA; Moyle G; Linney A; Reilly G; Edwards SG
    HIV Med; 2009 Jul; 10(6):351-5. PubMed ID: 19490181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.